|Bid||0.00 x 1000|
|Ask||0.00 x 1200|
|Day's Range||5.10 - 5.39|
|52 Week Range||4.82 - 14.62|
|Beta (3Y Monthly)||2.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.43|
PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells.
PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Shares of Adaptimmune Therapeutics PLC slumped 21% in morning trade Monday, after the results from a trial of its cancer treatment prompted Raymond James to slash its price target. The biopharmaceutical company said over the weekend that it was encouraged by the safety data from ongoing studies of SPEAR T-cells, but said no patients were treated in a Cohort 2 "triple tumor" study because the Safety Review Committee recommended an escalated dose. Raymond James analyst Reni Benjamin cut his target to $16 from $20, as the true efficacy of the product may only be determined at the higher, 5-billion-cell dose level. "Although still early, we believe higher doses will likely need to be evaluated with a larger population," Benjamin wrote in a note to clients. "We are decreasing our probability of success from 35% to 25% as we await a stronger correlation between dose, persistence, and clinical response." The stock has slumped 19% over the past three months but was still up 27% year to date, while the S&P 500 has slipped 1.2% the past three months and has gained 3.6% this year.
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PHILADELPHIA and OXFORD, United Kingdom, Oct. 08, 2018 -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today.
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adaptimmune Therapeutics PLC Sponsored ADR (NASDAQ: ADAP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 ...